Coloplast downgrades organic growth guidance

The medtech firm has announced a smaller adjustment to its full-year outlook for organic growth, going to 6–7% from 7%, due to the pandemic’s impact in China.

Photo: Coloplast / PR

Danish medtech firm Coloplast has released figures for the second quarter of fiscal 2021/2022, as well as a downgrade to the firm’s organic growth guidance.

According to Thursday’s report, Coloplast is now expecting 6–7% organic growth for the full year, which is an adjustment from the previously reported 7%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs